Holen Sie sich die Stockscreener-App
39.05
0.96%
-0.38
Schlusskurs vom Vortag:
$39.43
Offen:
$39.21
24-Stunden-Volumen:
9.12M
Relative Volume:
0.97
Marktkapitalisierung:
$172.28B
Einnahmen:
$50.91B
Nettoeinkommen (Verlust:
$18.95B
KGV:
9.1645
EPS:
4.261
Netto-Cashflow:
$1.92B
1W Leistung:
+0.57%
1M Leistung:
+2.31%
6M Leistung:
+1.38%
1J Leistung:
-26.64%
1-Tages-Spanne:
$38.75
$39.29
1-Wochen-Bereich:
$38.35
$39.77
52-Wochen-Spanne:
$35.12
$64.16
Novo Nordisk Adr Stock (NVO) Company Profile
Compare NVO vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
39.05 | 172.28B | 50.91B | 18.95B | 1.92B | 4.261 |
LLY
Lilly Eli Co
|
1,273.46 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.81 | 635.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.64 | 504.76B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.27 | 358.41B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.24B | 54.66B | 13.58B | 16.05B | 7.0171 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-11 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2026-08-27 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2026-08-12 | Herabstufung | Berenberg | Buy → Hold |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-18 | Eingeleitet | Bernstein | Outperform |
| 2026-03-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-03-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2026-03-02 | Herabstufung | Goldman | Buy → Neutral |
| 2026-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2026-02-24 | Herabstufung | Kepler | Buy → Hold |
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-12 | Hochstufung | Jefferies | Underperform → Hold |
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2025-12-08 | Herabstufung | Argus | Buy → Hold |
| 2025-10-27 | Fortgesetzt | Jefferies | Underperform |
| 2025-10-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-29 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-09-16 | Hochstufung | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-31 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-04-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | Hochstufung | Kepler | Hold → Buy |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Neutral |
| 2023-12-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Eingeleitet | Argus | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2022-07-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Herabstufung | UBS | Neutral → Sell |
| 2022-06-27 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-04-25 | Hochstufung | Cowen | Market Perform → Outperform |
| 2022-04-12 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Herabstufung | Liberum | Hold → Sell |
| 2021-12-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-07-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-05-11 | Herabstufung | UBS | Buy → Neutral |
| 2020-05-04 | Eingeleitet | Cowen | Market Perform |
| 2020-03-16 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-11-18 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-30 | Herabstufung | Jefferies | Hold → Underperform |
| 2019-06-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2017-12-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
Alle ansehen
Novo Nordisk Adr Aktie (NVO) Neueste Nachrichten
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances - Zacks Investment Research
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? - Zacks Investment Research
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility - The Motley Fool
Where Will Novo Stock Be in 10 Years? - The Motley Fool
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? - The Motley Fool
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market - Zacks Investment Research
$Novo-Nordisk A/S (NVO.US)$ A bullish breakout above the 25-day moving average carries a 70% probability of further upside. It is even more favorable if today's closing price is higher than yesterday's and there is no upper shadow. - Moomoo
Orbis Medicines signs USD 1.4 billion deal with Novo Nordisk - Greater Geneva Bern area (GGBa)
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug Competition - Yahoo Finance
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data - TipRanks
Novo's CagriSema helped women lose 25% of weight on average, analysis shows - Reuters
Prothena's Partnership Strategy: Growth Driver or Limitation? - Zacks Investment Research
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis - CNBC
Denmark’s Novo-Fueled Economy Faces Lower Growth, Watchdog Says - Bloomberg.com
Price to earnings forward of Novo Nordisk A/S Class B – LSIN:0QIU - TradingView
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Zacks Investment Research
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Novo Nordisk (NVO) repurchased 39.1 million B shares; treasury shares total 1.2% of share capital. - Stock Titan
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Zacks Investment Research
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? - Yahoo Finance
Novo Nordisk A/Sshare repurchase programme - GlobeNewswire
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. - The Motley Fool
The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool
Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher - The Motley Fool
Novo Nordisk and Eli Lilly Just Got Some Fantastic News - The Motley Fool
Novo Nordisk A/S (NVO) options chain - Yahoo Finance Australia
Novo-Nordisk A/S (NVO) Stock Forum and Discussion - Moomoo
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know - TradingKey
Novo Nordisk A/S Tokenized Stock (Coinbase) Price Today - CryptoRank
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Viking Therapeutics Starts Phase III Development of Obesity Pill - Zacks Investment Research
Novo Nordisk A/S : UBS remains Neutral - marketscreener.com
Novo Nordisk (NVO) Could Be 63% Undervalued Following Its Share Buyback - Yahoo Finance
Roche Expands Obesity Pipeline With Rona's RNAi Candidate - Zacks Investment Research
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now? - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum - Zacks Investment Research
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Zacks Investment Research
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today - Yahoo Finance
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Zacks Investment Research
Top Analyst Reports for Walmart, Visa & Novo Nordisk - Yahoo Finance
Novo Nordisk A/S: Dividend historical data and projections - marketscreener.com
GLP-1 weight-loss drugs slow biological aging, recent studies show - NewsNation
Finanzdaten der Novo Nordisk Adr-Aktie (NVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):